1. Introduction {#s0005}
===============

Tobacco use is the leading preventable cause of death, and is responsible for \> 480,000 deaths annually in the United States (U.S.) ([@bb0185]). The major causes of excess mortality among smokers stem from smoking-related cancers, cardiovascular disease and respiratory disease ([@bb0025], [@bb0105]). Although the past 4 decades have seen significant declines in the prevalence of smoking in the general population, prevalence remains high among certain populations ([@bb0135], [@bb0100]). Low-income persons ([@bb0135], [@bb0100]), racial/ethnic minorities ([@bb0100], [@bb0020]), persons with mental health disorders or substance use disorders ([@bb0150]), indigent persons living with HIV/AIDS ([@bb0190]), and persons who are uninsured or publicly insured ([@bb0040]), bear a disproportionate burden of tobacco-related morbidity and mortality ([@bb0030]).

Primary care clinicians are in a unique position to help patients quit smoking by employing strategies outlined in the U.S. Public Health Service guidelines ([@bb0070]). These guidelines recommend that all clinicians offer brief interventions for smoking cessation at all or nearly all encounters using the 5As (Ask about smoking, Advise cessation, Assess readiness to quit, Assist with motivation and/or cessation, and Arrange follow-up) ([@bb0070]) Most smokers in the general population are interested in quitting smoking and almost half attempt to quit smoking yearly ([@bb0035]). Smokers are receptive to counseling for smoking cessation ([@bb0070]), and about half report having received advice to quit from a health professional ([@bb0035], [@bb0115]). Most smokers cite clinician\'s advice to quit smoking as an important motivator for smoking cessation ([@bb0115], [@bb0075]). Receipt of clinician-delivered counseling, in particular the more intensive Assist and Arrange interventions for smoking cessation has been shown to increase cessation ([@bb0070], [@bb0130]). Receipt of all the 5As compared to one or none during a clinical encounter has been associated with increased use of cessation services ([@bb0120]).

Despite patients\' interest in receiving counseling, there is significant variability in clinician delivery of the 5As ([@bb0130], [@bb0060], [@bb0180]). Previous research has shown that while most smokers are screened for tobacco use, fewer are advised to quit or assessed for their readiness to quit, and only a minority report receipt of clinician-delivered Assist (pharmacotherapy and/or more intensive counseling) or Arrange ([@bb0130], [@bb0060], [@bb0095]). Fewer than 25% of Medicaid-enrolled smokers reported receiving assistance with cessation ([@bb0045]). Racial/ethnic minorities, persons of lower socioeconomic status, and younger persons are less likely to receive clinician-delivered cessation interventions ([@bb0055], [@bb0005], [@bb0065]). Patient comorbidity and time spent with the physician are also associated with lower probability of receiving smoking cessation interventions in clinical care ([@bb0100], [@bb0060], [@bb0160]).

In this study, we examined the prevalence of receipt of clinician-delivered 5As among patients in two diverse primary care clinics and one HIV care clinic and patient-related factors associated with receipt of the 5As. Consistent with previous studies ([@bb0130], [@bb0060], [@bb0095]), we hypothesized that receipt of Ask, Advise, and Assess would be higher than Assist and Arrange. We hypothesized that receipt of 5As would vary by clinic because of the distribution of patient comorbidity, and that patients with HIV/AIDS and those with mental health disorders or substance use disorders would be less likely to receive 5As. Among a subgroup of patients and their clinicians, we examined the indirect association between patient-reported receipt of 5As and clinician-reported overall adherence to 5As during their clinical practice.

2. Methods {#s0010}
==========

2.1. Study patients and sampling {#s0015}
--------------------------------

This study includes the analysis of cross-sectional data from the pre-implementation evaluation of patients and clinicians who were enrolled in a larger study of a randomized controlled trial of a computer tablet intervention to increase clinician adherence to 5As ([@bb0110]). We recruited patients and clinicians from 3 diverse clinics: an academic general internal medicine practice in a University-affiliated public hospital ("site 1"), an academic general internal medicine practice at a University-affiliated hospital ("site 2"), and an academic HIV practice at a University-affiliated public hospital ("site 3") ([@bb0110]). Data were collected between August 2013 and March 2014.

We recruited current smokers (i.e. having smoked at least 100 cigarettes in their lifetime and having smoked at least 1 cigarette in the past 7 days) who were 18 years or older, Spanish- or English-speaking, and engaged in primary or urgent care in any of the 3 clinics. We recruited clinicians, including post-graduate trainees, who were in internal medicine or family medicine specialties, engaged in patient care in one of the three clinic sites, and planned to continue to work in their current location for at least 1 year. All study protocols were approved by the University of California San Francisco, Committee on Human Research.

2.2. Study procedures {#s0020}
---------------------

Trained research staff approached patients in clinic waiting rooms prior to their primary care or urgent care clinic visits (i.e. the index clinic visit). Research staff screened patients for eligibility, enrolled patients into the study, and obtained written informed consent. Research staff administered a brief demographic questionnaire prior to the index visit, and a post-visit questionnaire (either in person or by telephone) on tobacco use behaviors and receipt of the 5As within 72 h of their visit. We were unable to complete all of the follow-up assessments by phone because some patients lacked functioning telephones. If the patient was unsure that he or she could be contacted by telephone, we completed the follow-up assessment in person. Patients received a \$20 gift card for completing the pre- and post-visit questionnaires.

We recruited and consented clinicians by email, and asked them to complete a self-administered online questionnaire about demographics, tobacco use behaviors, and adherence to 5As counseling. Clinician assessments took place at a different time, and were unrelated to the patients\' index visits. We gave clinicians a \$25 gift card for completing the questionnaire.

2.3. Study measures {#s0025}
-------------------

### 2.3.1. Patients {#s0030}

Prior to the index visit, patients self-reported information on: demographics (age and sex); race/ethnicity (Hispanic/Latino, White, Black or African American, Asian, Native Hawaiian or Other Pacific Islander, American Indian or Alaskan Native, Other/Mixed); and education (less than high school, high school or general education development, some college, or college degree or more). Patients self-reported whether they had health insurance, and if they did, they reported the type (Medicare, Medi-Cal or Medicaid, HMO or PPO, Healthy San Francisco or Healthy Worker, Other). Research staff confirmed with clinic staff whether patients were seeking primary or urgent care on the day of the visit. We estimated average daily cigarette consumption from patient self-reports of the number of days smoked and the number of cigarettes smoked per day. We obtained information on time to first cigarette after waking, and dichotomized responses as \< 30 min and ≥ 30 min.

After the index visit, we asked patients to self-report receipt of the 5As during that visit. We asked patients whether their clinician had asked about their smoking, advised them to quit smoking, assessed their readiness to quit smoking, assisted them in building motivation and/or their smoking cessation attempt, and arranged for follow-up. Patients self-reported whether they had received each of the Assist components, as defined in the clinical practice guidelines ([@bb0070]), including: planning to set a quit date, willingness to take steps to get ready to stop smoking, addressing roadblocks to quitting smoking, obtaining tips to cope with cigarette cravings, receiving patient education about quitting smoking, receiving information on outside resources for cessation (e.g. telephone quit line), obtaining information on smoking cessation medications, receiving a prescription for a cessation medication, and setting a quit date at that visit.

We extracted data on patient comorbidities from the clinical records using ICD-9 codes. We focused on the following comorbidities that may be associated with receipt of 5As: HIV (V08, 042.x--044.x), mental health disorders (300.x, 296.x, 295.x, 309.81, 311.x), drug dependence (304.x, 305.x), alcohol dependence (393.x), cancer (140.x--172.x, 174.x--195.8, 200.x--208.x, 238.6), pulmonary disease (490.x--505.x, 506.5, 416.7, 416.9, 508.1, 508.8), cerebrovascular disease (430.x-438.x, 362.34), cardiovascular disease (401.x--405.x, 410.x--414.x, 440.x, 444.x), and glaucoma (365.x).

### 2.3.2. Clinicians {#s0035}

Clinicians self-reported information on demographics (age and sex) and race/ethnicity (Hispanic/Latino, Black or African American, Asian or Pacific Islander, White, Native American or Alaskan Native, Other/Mixed). We obtained information on clinicians\' primary practice location, primary degree, number of years in clinical practice (0--2 years, 2--5 years, 5--10 years, 10--20 years, \> 20 years), and the time that they spent in direct patient care (0%--40%, 41%--80%, 81%--100%). Clinicians self-reported whether they had ever smoked at least 100 cigarettes in their lifetime. Ever smokers self-reported whether they were current smokers. We asked clinicians how frequently they adhered to the 5As \[Ask, Advise, Assess, Assist (encourage to set a quit date, discuss medications, or refer to smoking cessation treatment) ([@bb0070]), and Arrange\] overall in their outpatient practice using the following response options: "Never", "Rarely", "Some of the time", "Most of the time", or "Always". Clinicians also reported whether they had heard about the 5As, whether they had received training to administer the 5As, whether they would be interested in more 5As training, and the proportion of their patients who were smokers.

2.4. Statistical analysis {#s0040}
-------------------------

We reported sample characteristics for patients and clinicians using means (SD) for continuous variables and proportions for categorical variables. We reported the patient-reported receipt of each of the 5As. We examined the bivariate association of receipt of the 5As and patient demographics, clinic site, and tobacco use characteristics using logistic regression analysis accounting for clustering of patients within providers. We conducted logistic regression analyses with a backward elimination algorithm, adjusting for patient demographics, visit type, insurance status, clinic site, tobacco use characteristics, and patient comorbidities. Covariates with a *p*-value of 0.2 or lower were retained.

We examined adherence to the 5As among clinicians, and categorized responses as "Never", "Rarely or Sometimes", or "Most of the time or Always". We examined the bivariate association of clinician adherence to the 5As by clinician demographics, clinic site, and clinical practice characteristics using the chi-square statistic for categorical variables and the *t*-test for continuous variables. For the sub-sample of patients who had a study clinic visit with one of the participating clinicians, we fit logistic regression models to examine the indirect association between patient-reported receipt of the specific 5As components and clinician adherence to the same components. We did this to obtain a global assessment, as opposed to a visit-specific assessment, of the communication between patients and clinicians around the 5As for smoking cessation. Models for each component of the 5As were adjusted for patient demographics, visit type, insurance status, clinic site, tobacco use characteristics, and clinician report of the corresponding 5As. All analyses were conducted using Stata, version 11.

3. Results {#s0045}
==========

3.1. Patient-reported receipt of the 5As {#s0050}
----------------------------------------

We recruited 493 patients, of whom 462 (93.7% response rate) patients completed the pre- and post-index visit questionnaires. The analytic sample included 462 patients, with 16.7% were enrolled in site 1, 23.6% were enrolled in site 2, and 59.7% were enrolled in site 3 ([Table 1](#t0005){ref-type="table"}). Average age was 50.8 years (SD 11.2), 67.3% were male, and 42.2% were African American. The majority (79.4%) were current daily smokers and nearly two-thirds (60.9%) smoked within 30 min of waking. The majority of patients had at least one mental health disorder (79.9%) or a drug dependence disorder (88.1%).

Sites 1 and 3 served predominantly underserved populations. Patients in site 1 (55.8%) had a higher proportion of African American patients compared to site 2 (40.4%) and site 3 (39.1%) (*p* \< 0.003) ([Table 1](#t0005){ref-type="table"}). Patients in site 1 were more likely to be older (54.8 years) compared to site 2 (52.6 years) and site 3 (48.7%) (*p* \< 0.001). Patients in site 1 (27.8%) were more likely to report receiving medical coverage through the Healthy San Francisco program for uninsured patients compared to patients in site 2 (5.5%) and site 3 (18.6%) (*p* \< 0.001). Patients in site 1 had more comorbidities than patients in the other 2 sites.

The patient-reported prevalence of 5As receipt during their index visit was as follows: 49.9% Ask; 47.2% Advise; 40.6% Assess; 44.9% any Assist; 22.4% Arrange, and 14.5% for all 5As ([Fig. 1](#f0005){ref-type="fig"}A). The least frequently reported types of Assist included receiving prescriptions for smoking cessation (6.5%) and assistance with setting a quit date (7.6%; [Fig. 1](#f0005){ref-type="fig"}B).

In bivariate analyses, older patient age was associated with increased receipt of 5As ([Supplementary Table 1](#ec0005){ref-type="supplementary-material"}, [Supplementary Table 2](#ec0010){ref-type="supplementary-material"}). Patients in site 3 were less likely to report having received Ask, Advise, Assess, or any Assist components of 5As compared to patients in site 1. In multivariable models, older patient age was associated with higher odds of receipt of Advise, Assess, and Assist interventions ([Table 2](#t0010){ref-type="table"}). Patients in site 3 had a lower likelihood of being asked about tobacco use (AOR 0.3, 95% CI 0.2--0.6) than those in site 1 ([Table 3](#t0015){ref-type="table"}). Patients with HIV had a lower likelihood of being advised (AOR 0.5, 95% CI 0.3--0.8) or assessed (AOR 0.6, 95% CI 0.4--0.9) than those without. Patients with pulmonary disease had a higher likelihood of being assisted (AOR 1.8, 95% CI 1.1--2.8) and patients with cardiovascular disease had a higher likelihood of having follow-up arranged (AOR 2.2, 95% CI 1.3--3.8) than patients without these diagnoses ([Table 3](#t0015){ref-type="table"}). Patients with cardiovascular disease had a higher likelihood of reporting receipt of all the 5As during the index visit (AOR 1.9, 95% CI 1.1--3.5).

3.2. Clinician-reported adherence to the 5As {#s0055}
--------------------------------------------

Of the 61 clinicians, 39.3% reported working in site 1, 42.6% reported working in site 2, and 18.0% reported working in site 3 ([Table 3](#t0015){ref-type="table"}). The majority of clinicians were physicians (88.5%). Of the clinicians, 11.5% reported being ever smokers; none of them currently smoked. Almost all (90.2%) had heard of the 5As, 72.1% had received training for 5As, and 80.3% reported being interested in receiving more training to implement the 5As.

Almost all clinicians reported that during clinical encounters they had asked their patients about smoking (91.8%), advised them to quit smoking (91.8%), and assessed their readiness to quit (93.4%) "most of the time" or "always" ([Fig. 2](#f0010){ref-type="fig"}A). About two-thirds (65.7%) reported assisting patients with a quit attempt, a minority (19.7%) reported arranging for a follow-up, and a minority (18.0%) reported adhering to all the 5As either "most of the time" or "always" during clinical encounters. Among Assist components, 42.6% reported having assisted patients with setting a quit date, 52.5% discussed medications for cessation, and 37.7% provided referrals to smoking cessation resources "most of the time" or "always" during clinical encounters ([Fig. 2](#f0010){ref-type="fig"}B). Clinician demographics and practice characteristics were not associated with adherence to the 5As (data not shown).

3.3. Association of patient-reported receipt of the 5As with clinician-reported adherence to the 5As {#s0060}
----------------------------------------------------------------------------------------------------

The 61 clinicians cared for 214 of the sampled patients ([Supplementary Table 3](#ec0015){ref-type="supplementary-material"}). In subgroup analysis of patient and clinician clusters, clinician-report of having advised patients to quit smoking "most of the times" or "always" during clinical encounters was positively associated with patient-report of receipt of Advise (AOR 1.9, 95% CI 1.1--3.6) during the index visit. Clinician-report of arranging follow-up overall during clinical encounters was negatively associated with patients\' corresponding self-report of receipt of Arrange (AOR 0.3, 95% CI 0.1--0.8) during the index visit. Clinician-report was not associated with patient report of the other 5As. Clinician report of all the 5As "most of the times" or "always" during clinical encounters was negatively associated with patient-report of receipt of all the 5As during the index visit (AOR 0.03, 95% CI 0.002--0.8).

4. Discussion {#s0065}
=============

In this study of patients seeking care in primary care and HIV clinics, patient-reported receipt of some components of the 5As was lower than the national average and among commercially insured patients. In a nationally representative sample of patients seeking ambulatory care in the U.S. between 2005 and 2009, 62.7% were screened for tobacco use ([@bb0095]) and among commercially insured patients 90% were screened for tobacco use by clinicians ([@bb0140]) compared to 49.9% in our study. Prevalence of receiving advice to quit (40.9%) was higher among our patients compared to a nationally representative sample of patients seeking ambulatory care (20.9%) ([@bb0095]) but lower than commercially insured patients (71%) ([@bb0140]) Consistent with our hypothesis, patient reports of Assist and Arrange interventions were low and comparable to other patient populations in the U.S. ([@bb0130], [@bb0095], [@bb0140]).

In the U.S., tobacco use is concentrated among low-income populations, those with low educational attainment, racial/ethnic minority groups, persons with mental health disorders and substance use disorders ([@bb0135], [@bb0100], [@bb0150]). These high-risk populations were overrepresented in our study: about half of the patients had high school or less than high school education, two-thirds belonged to racial/ethnic minority groups, two-thirds were publicly insured, and the majority of patients had a diagnosis of mental health disorders or substance use disorders. Although guidelines recommend screening all patients for tobacco use ([@bb0070]), only half the patients self-reported being asked about their smoking and fewer received the other 5As despite being at high risk for tobacco use ([@bb0030]).

As in previous studies ([@bb0140]), with the exception of age no other demographic or tobacco use characteristics were associated with receipt of the 5As. Some clinicians may believe that younger patients are not motivated to quit smoking ([@bb0125]). Patients with cardiovascular or pulmonary disease were more likely to receive Assist or Arrange interventions, suggesting that clinicians may be better at counseling patients for secondary prevention rather than primary prevention ([@bb0090]).

Consistent with our hypothesis, patients in an HIV care clinic were less likely to report being asked, advised or assessed for smoking cessation compared to those in general medicine clinics. Persons living with HIV/AIDS have high rates of smoking ([@bb0190], [@bb0015]) and other medical and psychiatric comorbidities ([@bb0155]) that may influence receipt of the 5As. Cigarette smoking is an independent risk factor for all-cause mortality among patients living with HIV/AIDS ([@bb0050], [@bb0085]). Our findings highlight disparities in receipt of 5As among patients living with HIV/AIDS, and suggest the need for targeted interventions for this population.

Clinician-reported adherence to Ask, Advise, and Assess was higher than what has been reported in previous studies, where estimates of provider-delivered Ask, Advise, and Assess has ranged between 60% and 75% ([@bb0080], [@bb0145]). However, patient and clinician self-reports of Assist and Arrange were low. Receipt of these more intensive stages have been associated with increased quitting success and greater abstinence rates ([@bb0130], [@bb0140], [@bb0170]). Our findings have implications for improving clinician training on providing more intensive cessation interventions.

Although one-fourth of patients reported receiving information on medications for cessation, only a minority (6.5%) were prescribed medications during their last visit. The Affordable Care Act mandates coverage of treatment of tobacco dependence; however, significant state-level barriers exist in receipt of treatment ([@bb0165]). These include prior authorization requirements, annual limits on quit attempts, limits on duration, and required copayments, which may limit prescribing behavior among clinicians and accessibility among patients ([@bb0165]). Receipt of medications may also depend on patients\' interest in quitting, with unmotivated patients less likely to receive medications than those who are motivated to quit smoking ([@bb0140]). Clinician-level barriers may include lack of knowledge on prescribing medications for cessation or inadequate time to discuss medications among patients with medical and psychiatric comorbidities ([@bb0180]).

Although not a direct comparison, our findings of a discrepancy between patient-reported receipt of Arrange and clinician-report suggests that clinicians could be overestimating the rate at which they counsel patients or that patients may not comprehend clinician-delivered counseling. Clinicians may arrange follow-up without communicating that smoking cessation was the intent for follow-up; thus patient perceptions of Arrange may be different from that of clinicians. Interventions that rely on a personalized, mutually-agreed upon plan between patients and clinicians could increase receipt of interventions among smokers ([@bb0110], [@bb0195]). Receipt of all the 5As among patients and adherence to all the 5As among clinicians was low. A previous study reported that receipt of all the 5As among current smokers was associated with increased use of medications and counseling services ([@bb0120]). Clinicians may not have provided assist and arrange interventions if patients were unwilling to quit smoking. Our findings highlight implications of addressing all 5As irrespective of patients\' readiness to quit smoking.

Our study had several limitations. Smoking status was assessed via self-report, which could lead to misclassification bias. However, self-report has been shown to be a reliable measure of smoking status among diverse patient populations ([@bb0175], [@bb0010]). Clinicians\' adherence to the 5As was assessed by self-report of their overall practice rather than for the specific visit with the enrolled patient, limiting our ability to measure visit-level concordance between clinicians\' and patients\' self-reports. We were unable to determine whether receipt of Assisting and Arranging efforts were associated with patients\' degree of motivation to quit smoking.

The diversity of our patient population suggests that findings could be generalizable to other high-risk populations seeking care in public primary care and HIV clinics. Despite guidelines that emphasize counseling for tobacco use for all patients, findings indicate low levels of cessation interventions among a vulnerable patient population that is at high risk for tobacco-related morbidity and mortality. Disparities in receipt of the 5As appeared to be heightened for persons living with HIV and AIDS. These findings highlight opportunities for implementing interventions that rely on a personalized, jointly agreed upon plan between patients and clinicians, and that harnesses the potential of information technology to facilitate clinician-delivered 5As for patients in primary care and HIV care clinics.
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###### 

Patient demographics and tobacco use characteristics.

Table 1

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                            Total\               Site 1\              Site 2\              Site 3\              *P*-value
                                                                            *N* = 462\           *N* = 77\            *N* = 109\           *N* = 276\           
                                                                            Mean (SD) or N (%)   Mean (SD) or N (%)   Mean (SD) or N (%)   Mean (SD) or N (%)   
  ------------------------------------------------------------------------- -------------------- -------------------- -------------------- -------------------- -----------
  Age                                                                       50.8 (11.2)          54.8 (10.3)          52.8 (13.3)          48.8 (10.1)          \< 0.001

  Sex                                                                                                                                                           

   Female                                                                   142 (30.7)           33 (42.9)            56 (51.4)            53 (19.2)            \< 0.001

   Male                                                                     311 (67.3)           44 (57.1)            53 (48.6)            214 (77.5)           

   Transgender/other                                                        9 (1.95)             0 (0.0)              0 (0.0)              9 (3.3)              

  Race/ethnicity                                                                                                                                                

   White                                                                    142 (30.7)           16 (20.8)            36 (33.0)            90 (32.6)            \< 0.003

   African American                                                         195 (42.2)           43 (55.8)            44 (40.4)            108 (39.1)           

   Hispanic/Latino                                                          84 (18.2)            12 (15.6)            15 (13.8)            57 (20.7)            

   Asian                                                                    10 (2.2)             3 (3.9)              2 (1.8)              5 (1.8)              

   Native Hawaiian/PI                                                       2 (0.4)              0 (0.0)              1 (0.9)              1 (0.4)              

   American Indian/Alaskan native                                           12 (2.6)             0 (0.0)              1 (0.9)              11 (3.9)             

   Other/Mixed                                                              17 (3.7)             3 (3.9)              10 (9.2)             4 (1.5)              

  Education                                                                                                                                                     \< 0.03

   Less than high school                                                    88 (19.1)            17 (22.1)            11 (10.1)            60 (21.7)            

   High school or GED                                                       141 (30.5)           22 (28.6)            28 (25.7)            91 (32.9)            

   Some college                                                             177 (38.3)           31 (40.3)            52 (47.7)            94 (34.1)            

   College degree or more                                                   56 (12.1)            7 (9.1)              18 (16.5)            31 (11.2)            

  Health insurance                                                                                                                                              \< 0.001

   None                                                                     12 (2.6)             5 (6.5)              0 (0.0)              7 (2.5)              

   HMO/PPO                                                                  34 (7.4)             3 (3.9)              27 (24.8)            4 (1.5)              

   Healthy San Francisco/healthy workers[a](#tf0005){ref-type="table-fn"}   76 (16.5)            20 (25.9)            6 (5.6)              50 (18.1)            

   Medi-Cal                                                                 52 (11.3)            12 (15.6)            10 (9.2)             30 (10.9)            

   MediCal/MediCare                                                         249 (53.9)           27 (35.1)            51 (46.8)            171 (61.9)           

   Other                                                                    19 (4.1)             5 (6.5)              2 (1.8)              12 (4.4)             

  Type of visit                                                                                                                                                 0.9

   Urgent care                                                              82 (17.7)            13 (16.9)            19 (17.4)            50 (18.1)            

   Primary care                                                             380 (82.3)           64 (83.1)            90 (82.6)            226 (81.9)           

  Clinics[b](#tf0010){ref-type="table-fn"}                                                                                                                      

   Site 1                                                                   77 (16.7)            \--                  \--                  \--                  

   Site 2                                                                   109 (23.6)           \--                  \--                  \--                  

   Site 3                                                                   276 (59.7)           \--                  \--                  \--                  

  Smoking status[c](#tf0015){ref-type="table-fn"}                                                                                                               \< 0.02

   Current daily                                                            365 (79.4)           63 (81.8)            76 (69.7)            226 (82.5)           

   Current non-daily                                                        95 (20.7)            14 (18.2)            33 (30.3)            48 (17.5)            

  Average daily cigarette consumption[c](#tf0015){ref-type="table-fn"}      10 (8.4)             10.1 (8.3)           9.0 (7.6)            10.4 (8.7)           0.9

  Time to first cigarette after waking[c](#tf0015){ref-type="table-fn"}                                                                                         0.3

   30 min or less                                                           280 (60.9)           46 (59.7)            60 (55.1)            174 (63.5)           

   ≥ 30 min                                                                 180 (39.1)           31 (40.3)            49 (44.9)            100 (36.5)           

  Comorbidities                                                                                                                                                 

   HIV                                                                      270 (58.4)           5 (6.5)              0 (0.0)              265 (96.0)           \< 0.001

   Cancer                                                                   74 (16.0)            9 (11.7)             17 (5.6)             48 (17.4)            0.5

   Mental health disorders[d](#tf0020){ref-type="table-fn"}                 369 (79.9)           57 (74.0)            87 (79.8)            225 (81.5)           0.3

   Alcohol dependence                                                       78 (16.9)            23 (29.9)            8 (7.3)              47 (17.0)            \< 0.001

   Drug dependence                                                          407 (88.1)           71 (92.2)            93 (85.3)            243 (88.0)           0.4

   Cerebrovascular disease                                                  43 (9.3)             13 (16.9)            10 (9.2)             20 (7.3)             \< 0.04

   Pulmonary disease                                                        101 (21.9)           45 (58.4)            55 (50.5)            1 (0.4)              \< 0.001

   Cardiovascular disease[d](#tf0020){ref-type="table-fn"}                  287 (62.1)           67 (87.0)            72 (66.1)            148 (53.6)           \< 0.001

   Glaucoma                                                                 29 (6.3)             4 (5.2)              12 (11.0)            13 (4.7)             0.07
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\-- Not applicable.

Healthy San Francisco is a program designed to make health care services available to uninsured San Francisco residents. Healthy Workers is a health insurance program administered by San Francisco Health Plan.

Site 1 is an academic general internal medicine practice in a University-Affiliated public hospital, Site 2 is an academic general internal medicine practice in a University-affiliated hospital, Site 3 is an HIV practice in a University-affiliated public hospital.

Data on cigarette smoking missing for 2 people.

Mental health disorders include Anxiety, Somatoform, dissociative disorder, bipolar disorder, schizophrenia, post traumatic stress disorder, and depression. Cardiovascular disease includes hypertension.

###### 

Multivariable logistic regression analysis with backward elimination of patient-related factors associated with receipt of 5As (*N* = 462).

Table 2

                                             AskAdjusted odds ratio (95% CI)[a](#tf0025){ref-type="table-fn"}   AdviseAdjusted odds ratio (95% CI)[a](#tf0025){ref-type="table-fn"}   AssessAdjusted odds ratio (95% CI)[a](#tf0025){ref-type="table-fn"}   AssistAdjusted odds ratio (95% CI)[a](#tf0025){ref-type="table-fn"}   ArrangeAdjusted odds ratio (95% CI)[a](#tf0025){ref-type="table-fn"}   All 5AsAdjusted odds ratio(95% CI)[a](#tf0025){ref-type="table-fn"}
  ------------------------------------------ ------------------------------------------------------------------ --------------------------------------------------------------------- --------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------
  Age[b](#tf0030){ref-type="table-fn"}       1.1 (0.9--1.2)                                                     1.1 (1.0--1.2)[\|\|](#tf0055){ref-type="table-fn"}                    1.1 (1.0--1.2)[\|\|](#tf0055){ref-type="table-fn"}                    1.1 (1.0--1.2)[¶](#tf0045){ref-type="table-fn"}                       \--[c](#tf0035){ref-type="table-fn"}                                   \--[c](#tf0035){ref-type="table-fn"}
  Sex                                                                                                                                                                                                                                                                                                                                                                                                    
   Male                                      Ref.                                                               Ref.                                                                  Ref.                                                                  Ref.                                                                  Ref.                                                                   Ref.
   Female                                    1.3 (0.9--1.8)                                                     1.4 (1.0--1.9)                                                        \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   \--[c](#tf0035){ref-type="table-fn"}
  Race/ethnicity                                                                                                                                                                                                                                                                                                                                                                                         
   Nonwhite                                  Ref.                                                               Ref.                                                                  Ref.                                                                  Ref.                                                                  Ref.                                                                   Ref.
   White                                     \--[c](#tf0035){ref-type="table-fn"}                               0.7 (0.5--1.1)                                                        0.7 (0.4--1.1)                                                        \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   0.6 (0.3--1.2)
  Clinics[d](#tf0040){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                               
   Site 1                                    Ref.                                                               Ref.                                                                  Ref.                                                                  Ref.                                                                  Ref.                                                                   Ref.
   Site 2                                    0.7 (0.4--1.2)                                                     \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   \--[c](#tf0035){ref-type="table-fn"}
   Site 3                                    0.3 (0.2--0.6)[\#](#tf0050){ref-type="table-fn"}                   \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   \--[c](#tf0035){ref-type="table-fn"}
  Average daily cigarette consumption        1.0 (0.9--1.0)                                                     1.0 (1.0--1.04)                                                       \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   1.0 (1.0--1.1)[\|\|](#tf0055){ref-type="table-fn"}
  Comorbidities                                                                                                                                                                                                                                                                                                                                                                                          
   HIV                                       \--[c](#tf0035){ref-type="table-fn"}                               0.5 (0.3--0.8)[¶](#tf0045){ref-type="table-fn"}                       0.6 (0.4--0.9)[\|\|](#tf0055){ref-type="table-fn"}                    \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   \--[c](#tf0035){ref-type="table-fn"}
   Mental health disorders                   0.7 (0.4--1.1)                                                     \--[c](#tf0035){ref-type="table-fn"}                                  0.7 (0.4--1.1)                                                        0.7 (0.5--1.1)                                                        0.7 (0.4--1.1)                                                         \--[c](#tf0035){ref-type="table-fn"}
   Drug dependence                           \--[c](#tf0035){ref-type="table-fn"}                               \--[c](#tf0035){ref-type="table-fn"}                                  1.5 (0.9--2.6)                                                        \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   \--[c](#tf0035){ref-type="table-fn"}
   Pulmonary disease                         \--[c](#tf0035){ref-type="table-fn"}                               \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  1.8 (1.1--2.8)[\|\|](#tf0055){ref-type="table-fn"}                    1.4 (0.9--2.3)                                                         1.5 (0.8--2.9)
   Cardiovascular disease                    \--[c](#tf0035){ref-type="table-fn"}                               \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  2.2 (1.3--3.8)[¶](#tf0045){ref-type="table-fn"}                        1.9 (1.1--3.5)[\|\|](#tf0055){ref-type="table-fn"}
   Glaucoma                                  \--[c](#tf0035){ref-type="table-fn"}                               \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                  \--[c](#tf0035){ref-type="table-fn"}                                   0.3 (0.1--1.7)

*P*-values were obtained from logistic regression analysis, accounting for clustering by provider.

The odds ratio represents the odds of receiving counseling for every 5-unit increase in age.

Variables were omitted from the model if *p* \> 0.2.

Site 1 is an academic general internal medicine practice in a University-Affiliated public hospital, Site 2 is an academic general internal medicine practice in a University-affiliated hospital, Site 3 is an HIV practice in a University-affiliated public hospital.

*p* \< 0.005.

*p* \< 0.001.

*p* \< 0.05.

###### 

Provider sample characteristics.

Table 3

  ---------------------------------------------------------------
                                             Total\
                                             *N* = 61\
                                             Mean (SD) or N (%)
  ------------------------------------------ --------------------
  Age                                        38.9 (10.6)

  Sex                                        

   Female                                    44 (72.1)

   Male                                      17 (27.9)

  Race/ethnicity                             

   White                                     39 (63.9)

   African American                          1 (1.6)

   Hispanic/Latino                           6 (9.8)

   Asian                                     12 (19.7)

   Native Hawaiian/PI                        0 (0.0)

   American Indian/Alaskan native            0 (0.0)

   Other/mixed                               3 (4.9)

  Education                                  

   Physician                                 54 (88.5)

   Nurse practitioner                        7 (11.5)

  Years in practice                          

   0--2 years                                21 (34.4)

   2--5 years                                8 (13.1)

   5--10 years                               7 (11.5)

   10--20 years                              19 (31.2)

   \> 20 years                               6 (9.8)

  Percentage of time spent in patient care   

   0%--40%                                   22 (36.1)

   41%--80%                                  17 (27.9)

   81%--100%                                 22 (36.1)

  Clinics[a](#tf0060){ref-type="table-fn"}   

   Site 1                                    24 (39.3)

   Site 2                                    26 (42.6)

   Site 3                                    11 (18.0)

  Smoking status                             

   Ever smoker                               7 (11.5)

   Current smoker                            0 (0.0)

  Heard of 5As                               55 (90.2)

  Received training for 5As                  44 (72.1)

  Interested in more 5As training            49 (80.3)

  Proportion of patients who smoke           

   0%--24%                                   24 (39.3)

   25%--49%                                  34 (55.7)

   50%--74%                                  2 (3.3)

   75%--100%                                 1 (1.6)
  ---------------------------------------------------------------

Site 1 is an academic general internal medicine practice in a University-Affiliated public hospital, Site 2 is an academic general internal medicine practice in a University-affiliated hospital, Site 3 is an HIV practice in a University-affiliated public hospital.
